PTGS2 and cancer: NSAIDs like Diclofenac, Mefenamic acid, Celecoxib, Naproxen, and Etoricoxib showed high binding affinity to PTGS2, indicating their potential to suppress TDM-1-resistant cancer cells by modulating inflammation and immune responses [64,65].